Powderject stock sinks further on delays to launch of anaesthetic

POWDERJECT PHARMACEUTICALS, one of the UK's most highly-rated biotechnology companies, fell from grace yesterday after revealing a delay of up to two years in the launch of its first product.

The lack of an expected announcement on a deal with SmithKline Beecham, the major pharmaceutical company, compounded a 15 per cent fall in the company's shares.

Powderject said the launch of Lidocaine, an anaesthetic which does not require a needle, could be set back by at least a year because it would now be aimed at children as well as adults. That would mean conducting further trials of the treatment on children, which are more complicated than those on adults.

Paul Drayson, chief executive of Powderject, said: "This was a difficult decision for Powderject to settle the way forward for the Lidocaine project. It would have been easier to stick with the adults-only strategy, but this is the best way to maximise the product in the long term."

He declined to indicate the size of the market for the expanded project but said the move would broadly double Lidocaine's sales.

The group was in advanced discussions with a marketing partner for Lidocaine, he added. However, he would not indicate a new launch date for Lidocaine, which had been expected to hit the market next year.

Dr Drayson also said Powderject's late-stage development of its patented powder-injection technology was taking longer than the company had expected at the time of its flotation in 1997.

Meanwhile, Powderject said its long-term future lay specifically in vaccine delivery. The group would be seeking to acquire both vaccines and vaccine companies in pursuit of its ambitions.

Speculation over a deal with SmithKline Beecham to market a Powderject vaccine for flu sent the shares to an all-time high of 1,005p last month.

Powderject also said a partnership with Boehringer Mannheim on a kidney disease treatment had been terminated.

The news sent the shares 152.5p lower to 830p, wiping pounds 110m from the value of company, now capitalised at pounds 620m. Dr Drayson and his family own a 17 per cent stake.

The company also unveiled positive data on phase two trials of Alprostadil, a treatment for impotent men who can't take oral treatments such as Viagra.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Customer Relations Officer

£13000 per annum: Recruitment Genius: This is an exciting opportunity to join ...

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Recruitment Genius: Evening Administrator

£8 per hour: Recruitment Genius: This Pension Specialist was established early...

Guru Careers: Executive Assistant / PA

£30 - 35k + Bonus & Benefits: Guru Careers: We are seeking an Executive Assist...

Day In a Page

Homeless Veterans campaign: Donations hit record-breaking £1m target after £300,000 gift from Lloyds Bank

Homeless Veterans campaign

Donations hit record-breaking £1m target after huge gift from Lloyds Bank
Flight MH370 a year on: Lost without a trace – but the search goes on

Lost without a trace

But, a year on, the search continues for Flight MH370
Germany's spymasters left red-faced after thieves break into brand new secret service HQ and steal taps

Germany's spy HQ springs a leak

Thieves break into new €1.5bn complex... to steal taps
International Women's Day 2015: Celebrating the whirlwind wit of Simone de Beauvoir

Whirlwind wit of Simone de Beauvoir

Simone de Beauvoir's seminal feminist polemic, 'The Second Sex', has been published in short-form for International Women's Day
Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

Why would I want to employ someone I’d be happy to have as my boss, asks Simon Kelner
Confessions of a planespotter: With three Britons under arrest in the UAE, the perils have never been more apparent

Confessions of a planespotter

With three Britons under arrest in the UAE, the perils have never been more apparent. Sam Masters explains the appeal
Russia's gulag museum 'makes no mention' of Stalin's atrocities

Russia's gulag museum

Ministry of Culture-run site 'makes no mention' of Stalin's atrocities
The big fresh food con: Alarming truth behind the chocolate muffin that won't decay

The big fresh food con

Joanna Blythman reveals the alarming truth behind the chocolate muffin that won't decay
Virginia Ironside was my landlady: What is it like to live with an agony aunt on call 24/7?

Virginia Ironside was my landlady

Tim Willis reveals what it's like to live with an agony aunt on call 24/7
Paris Fashion Week 2015: The wit and wisdom of Manish Arora's exercise in high camp

Paris Fashion Week 2015

The wit and wisdom of Manish Arora's exercise in high camp
8 best workout DVDs

8 best workout DVDs

If your 'New Year new you' regime hasn’t lasted beyond February, why not try working out from home?
Paul Scholes column: I don't believe Jonny Evans was spitting at Papiss Cissé. It was a reflex. But what the Newcastle striker did next was horrible

Paul Scholes column

I don't believe Evans was spitting at Cissé. It was a reflex. But what the Newcastle striker did next was horrible
Miguel Layun interview: From the Azteca to Vicarage Road with a million followers

From the Azteca to Vicarage Road with a million followers

Miguel Layun is a star in Mexico where he was criticised for leaving to join Watford. But he says he sees the bigger picture
Frank Warren column: Amir Khan ready to meet winner of Floyd Mayweather v Manny Pacquiao

Khan ready to meet winner of Mayweather v Pacquiao

The Bolton fighter is unlikely to take on Kell Brook with two superstar opponents on the horizon, says Frank Warren
War with Isis: Iraq's government fights to win back Tikrit from militants - but then what?

Baghdad fights to win back Tikrit from Isis – but then what?

Patrick Cockburn reports from Kirkuk on a conflict which sectarianism has made intractable